## ADMA: ADMA Biologics Inc - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.34 indicates fundamental undervaluation. Quality metrics strong (ROE 63%, ROA 22%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($18.34)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Osterweis Capital Management Inc. Takes $5.40 Million Position in ADMA Biologics Inc $ADMA**
- Source: MarketBeat | 20251212T210848 | Somewhat-Bullish | Relevance: 100%
- Osterweis Capital Management Inc. has acquired a new position in ADMA Biologics Inc (NASDAQ:ADMA) worth approximately $5.40 million. This investment highlights strong institutional interest in the biotechnology company, with major firms like State Street, Geode Capital Management, and American Century also increasing their stakes. ADMA Biologics, which specializes in plasma-derived biologics, recently reported solid Q2 earnings, beating revenue estimates and reinforcing analyst confidence with a consensus "Buy" rating.

**2. Cim LLC Acquires New Holdings in ADMA Biologics Inc $ADMA**
- Source: MarketBeat | 20251214T100940 | Somewhat-Bullish | Relevance: 100%
- Cim LLC has acquired a new stake of 90,821 shares in ADMA Biologics Inc, valued at approximately $1.65 million, during the second quarter. Several other institutional investors also adjusted their positions in ADMA, with overall institutional ownership now standing at 75.68%. Despite a recent downgrade by Weiss Ratings from "buy" to "hold," the consensus analyst rating for ADMA Biologics remains a "Buy" with a price target of $28.50.

**3. Precision Trading with Adma Biologics Inc (ADMA) Risk Zones**
- Source: Stock Traders Daily | 20251213T165400 | Somewhat-Bearish | Relevance: 100%
- This article provides a precision trading analysis for Adma Biologics Inc (ADMA), highlighting neutral near-term readings and mid-term strong sentiment. It outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report also notes an exceptional 51.2:1 risk-reward short setup.

**4. ADMA Biologics Inc $ADMA Holdings Decreased by AWM Investment Company Inc.**
- Source: MarketBeat | 20251213T110848 | Neutral | Relevance: 100%
- AWM Investment Company Inc. reduced its stake in ADMA Biologics Inc. by 9.3% during the second quarter, now holding 2.2 million shares valued at $40.06 million, representing 4.5% of its portfolio. Despite this, several other institutional investors increased their positions in ADMA Biologics. The company's stock has a "Buy" consensus rating and an average target price of $28.50, following its recent earnings report that met analyst expectations.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.08M) |
| Sells | 1 ($0.10M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.0% (-2.3%)
- Vanguard Group Inc: 8.8% (-1.8%)
- State Street Corpora: 5.7% (+12.3%)
- Invesco Ltd.: 5.2% (-2.4%)
- Sachem Head Capital : 3.8% (+100.0%)

### Key Risks

1. Elevated short interest (9.6%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.34 suggests fair value with growth premium. Forward P/E 20.6x attractive for 61% earnings growth. Quality metrics strong (ROE 63%, ROA 22%, margin 43%). Balance sheet: strong liquidity (7.1x), low leverage (D/E 0.32). Revenue growth strong at 24% YoY. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.7B |
| Beta | 0.43 |
| 52W Range | $13.50 - $25.67 |
| Short Interest | 9.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.34 |
| Forward P/E | 20.6 |
| Current P/E | 33.2 |
| YoY Growth | 61.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 7.8% to 6.8% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 85th percentile. MRS_5 at 0.9% confirms short-term momentum alignment. AM_20 at 7.0% shows strong absolute momentum above own 20MA. Outperforming sector by 7.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -FTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.76% (CS: 85) | Strong |
| RSI_14 | 65.1 | Neutral |
| MACD Histogram | 0.04 | Bullish |
| vs SMA20 | 1.070x | Above |
| vs SMA50 | 1.208x | Above |
| vs SMA200 | 1.094x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $19.78
- **Stop Loss:** $18.34 (7.3% risk)
- **Target:** $22.66 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 694
- **Position Value:** $13,727.32
- **Portfolio %:** 13.73%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-03-02 (Est: $0.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.16 | +2.6% |
| 2025Q2 | $0.14 | $0.14 | +7.4% |
| 2025Q1 | $0.17 | $0.11 | -33.3% |
| 2024Q4 | $0.15 | $0.14 | -9.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*